Spinal Muscular Atrophy Treatment Market Size to reach USD 14.49 Billion

The global spinal muscular atrophy treatment market size is expected to reach USD 14.49 billion by 2026, exhibiting a CAGR of 28.9% during the forecast period. The rising prevalence of rare diseases around the world will fuel demand for SMA treatment in the forthcoming years, which in turn will aid the growth of the market. As per the National Policy for the treatment of rare diseases, globally, around 6000 to 8000 rare diseases are estimated to exist with new rare diseases reported on a regular basis. Furthermore, 80% of all the rare diseases are genetically originated and therefore impact children inexplicably. The survey also revealed that 50% of new cases are in children and are responsible for 35% of deaths before the age of 1 year, 10% between the ages of 1 and 5 years and 12% between 5 and 15 years. Nonetheless, “the growing initiatives by government authorities for pre-diagnosis will impact the spinal muscular atrophy (SMA) treatment market share positively during the forecast period”, predicts our lead analysts at Fortune Business Insights.

Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/spinal-muscular-atrophy-treatment-market-100576

According to the report, published by Fortune Business Insights, titled “Spinal Muscular Atrophy (SMA) Treatment Market Size, Share and Global Trend By Product (Nusinersen and Onasemnogen Abeparvovec), By Disease Type (Type 1 SMA, Type 2 SMA and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Geography Forecast till 2026” the market size stood at USD 1.72 billion. The spinal muscular atrophy (SMA) treatment market report executes a PESTEL study and SWOT analysis to reveal the stability, restrictions, openings, and threats in the smart building market. Combined with the market analysis capabilities and knowledge integration with the relevant findings, the report has foretold the robust future growth of the SMA treatment market, and all articulated with geographical and merchandise segments. Moreover, it also shows different procedures and strategies, benefactors and dealers working in the market, explores components convincing market development, generation patterns, and following systems. Additionally, the figures and topics covered in this report are both all-inclusive and reliable for the readers.

Market Driver:

R&D Initiatives by Key Players to Spur Sales Opportunities 

The surge in research and development activities for the improvement of therapies and treatment options by key players will aid the spinal muscular atrophy (SMA) treatment market growth during the forecast period. Various drug pipeline for advanced stages of clinical trials by major pharmaceutical companies will augment the healthy growth of the market. For instance, Genentech/Roche’s pipeline candidate of Risdiplam, which recently received a priority review from the FDA and is expected to receive a decision on approval from the FDA by May 2020. Furthermore, the growing initiatives for pre-diagnosis and positive reimbursement policies will boost the spinal muscular atrophy (SMA) treatment market trends in the foreseeable future. Moreover, the growing awareness regarding pivotal treatment options will create new opportunities for the market.

protein hydrolysate market Previous post Global Protein Hydrolysates Market Size 2022 Scope, Size and Forecast to 2028 | Vantage Market Research
Next post Stomach Cancer/Gastric Cancer Treatment Market Size to reach USD 8.20 Billion [CAGR 15.3%]

Leave a Reply

Your email address will not be published.